Featured Publications

INOVIO is focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis

Laryngoscope
May 2023

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants

npj Vaccines
October 2021

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

The Journal of Infectious Diseases
January 2022

571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster

Open Forum Infectious Diseases
December 2021

Immunogenicity of a DNA vaccine candidate for COVID-19

Nature Communications
May 2020

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

The Lancet Infectious Diseases
July 2019

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

The Lancet
September 2015

HPV-Targeted

Title	Disease Target	Product
Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses Science Translational Medicine — October 2012	Cervical Dysplasia	VGX-3100
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100 Molecular Therapy Oncolytics — January 2016	Cervical Dysplasia	VGX-3100
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy Clinical Cancer Research — January 2018	Cervical Dysplasia	VGX-3100
Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis BMJ — July 2016	Cervical Dysplasia	VGX-3100
Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis Vaccines — January 2020	RRP	INO-3107
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer Clinical Cancer Research — January 2019	Head & Neck Cancer	MEDI0457
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial The Lancet — September 2015	Cervical Dysplasia	VGX-3100
Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis Laryngoscope — May 2023	Recurrent Respiratory Papillomatosis	INO-3107

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases